European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

PHASE3TerminatedINTERVENTIONAL
Enrollment

645

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
ObesityDyslipidemias
Interventions
DRUG

rimonabant

"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant"

DRUG

Placebo

Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.

Trial Locations (15)

Unknown

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Athens

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Dublin

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Lysaker

Sanofi-Aventis Administrative Office, Porto Salvo

Sanofi-Aventis Administrative Office, Bratislava

Sanofi-Aventis Administrative Office, Stockholm

Sanofi-Aventis Administrative Office, Meyrin

Sanofi-Aventis Administrative Office, Istanbul

Sanofi-Aventis Administrative Office, Guildford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY